Cameco Corporation

Thesis

Cameco is the only Western vertically integrated nuclear-fuel-cycle major — tier-one uranium mining, conversion, and 49% of Westinghouse — and we expect consolidated revenue to compound roughly 8%/yr through 2031 as legacy contracts reprice toward the US$90/lb long-term price and the US government's $80B AP1000 program converts into Westinghouse backlog. But at ~$90/share the market already pays ~15.6x consolidated TTM sales and ~73x TTM adjusted earnings for that future; our probability-weighted value is ~$42/share, roughly 0.46x the current price. The thesis is falsified operationally if the contract book, the long-term uranium price, or the Westinghouse government agreements break (see kill conditions) — and it fails our valuation gates today, so this publishes as a watchlist note, not a buy.

Why Now

The operating inflection is real and it is in the filings. Q1 2026 (6-K furnished 2026-05-05, quarter ended 2026-03-31): revenue C$845M, up 7% from C$789M; adjusted net earnings C$203M versus C$70M a year earlier (more than doubled); adjusted EBITDA C$509M, up 44%; uranium segment earnings before taxes C$358M versus C$227M, on 7.8M lb delivered (+13%) at a rising average realized price. That followed FY2025 (6-K furnished 2026-02-12): revenue C$3.48B versus C$3.14B in 2024, adjusted net earnings C$627M versus C$292M, adjusted EBITDA ~C$1.9B. The balance sheet is net cash — C$1.11B in cash and short-term investments against C$1.0B of debt at March 31, 2026, per the Q1 interim statements — with a US$49M Westinghouse distribution received in Q1 and a US$124M JV Inkai dividend received just after quarter-end.

The pricing regime shifted underneath these numbers. Cameco's Q1 2026 MD&A anchors its outlook on a UxC spot price of US$84.00/lb and a long-term indicator of US$90.00/lb as of March 31, 2026 — the long-term price's highest level since 2008 — and spot sat near US$85.7/lb in mid-July 2026. Cameco's 2026 guided average realized price of C$85.00–89.00/lb (roughly US$64–67/lb at their 1.33 USDCAD assumption) still lags the market badly because legacy contracts cap upside; as those roll off, realized price grinds up mechanically. The MD&A discloses commitments averaging over 28M lb/yr of deliveries for the next five years, front-loaded in 2026–2028, with 2026 sales guidance of 29–32M lb and revenue guidance of C$3,130–3,370M.

The Westinghouse leg changed category in the past nine months. On October 27, 2025, the US government announced an $80B strategic partnership with Westinghouse and its owners Brookfield (51%) and Cameco (49%) to deploy a fleet of AP1000 reactors, executed as a binding term sheet with the Department of Commerce; on June 23, 2026, the DOE announced a conditional US$17.5B loan commitment to finance long-lead components for up to 10 AP1000s. Cameco's Q1 2026 MD&A guides its 49% share of Westinghouse 2026 adjusted EBITDA to US$370–430M (Q1 share: C$122M versus C$92M, +33% YoY) — but states plainly that this outlook assumes definitive agreements with the US government are signed and work advances on at least one project this year. That conditionality is the honest hinge of the story.

Why write it up now rather than at the October 2025 announcement: the stock round-tripped from ~$69 to a $135.24 high and back to $90.37 (July 22, 2026 close), so the question of what the fundamentals actually support — versus what the announcement rally priced — is now answerable with two post-announcement quarters of filings. Our answer, below, is that the operating inflection is genuine but the price still capitalizes most of the bull case.

Business Quality

The moat is geology plus bifurcation. McArthur River/Key Lake and Cigar Lake are the two highest-grade uranium operations on earth (ore grades roughly 100x world average), producing 6.2M lb (Cameco's share) in Q1 2026 against 2026 guidance of 19.5–21.5M lb, with Key Lake licensed to 25M lb/yr — expansion headroom that requires no new permits. The fuel services segment (Port Hope conversion, guided 13–14M kgU in 2026, revenue C$590–630M) is one of only a handful of Western conversion assets in a market actively bifurcating away from Russian supply, which is why conversion prices have held near record levels. The 49% Westinghouse stake adds the installed-base annuity — fuel and outage services for the roughly half of the world's reactor fleet built on Westinghouse technology, with historic core margins of 16–19% per Cameco's MD&A — plus the AP1000 new-build option that the US government has now underwritten politically. Add 40% of JV Inkai (low-cost Kazakh ISR pounds, 10.4M lb 2026 target at 100%) and 49% of Global Laser Enrichment, and one ticker touches every stage of the Western fuel cycle.

Unit economics at current guidance: 2026 uranium realized price C$85–89/lb against unit cost of sales (including D&A) of C$61.50–65.00/lb — a ~30% per-pound gross margin that widens mechanically as sub-market legacy contracts expire. FY2025 adjusted EBITDA of ~C$1.9B on C$3.48B of consolidated revenue (55%, flattered by equity-accounted pickups) shows what the model produces at US$80+ uranium. The caveat: Westinghouse still loses money at the net line (Q1 2026 share of net loss C$46M) because of acquisition purchase accounting, ~US$120–135M of finance costs (Cameco share), and restructuring — the EBITDA is real but so is the capital structure underneath it.

Capital allocation is the strongest qualitative argument for management. Cameco held supply discipline through the decade-long bear market, keeping tier-two assets on care and maintenance (C$62–67M/yr of ongoing cost) rather than flooding the market, and bought 49% of Westinghouse counter-cyclically in 2022 at a US$7.9B enterprise value — a stake the market now implicitly values at several times that. Share count is essentially flat (435.3M to 435.6M diluted YoY), the balance sheet is net cash with a US$1.0B undrawn revolver, and there is no history of dilutive empire-building. Competition is thin: Kazatomprom produces cheaper pounds at greater volume but carries Kazakh custody, transit, and governance risk and offers no reactor-technology exposure; no Western peer integrates mining, conversion, and reactor services at any comparable scale. The structural weaknesses are commodity price-taking on the mining side, the long-running CRA transfer-pricing dispute (reassessments for 2003–2006 still being contested despite Cameco's 2021 Supreme Court win), and Inkai's operational fragility (the January 2025 production suspension).

Financial Base

Reference figures as of 2026-07-22: trailing-twelve-month revenue of $2,513M, 435.6M diluted shares, net debt of $-80M, and a share price of $90.37. Sources:

• 6-K furnished to SEC 2026-05-05 (Q1 2026 news release, MD&A and interim financial statements for quarter ended 2026-03-31) — revenue C$845.4M (vs C$789.4M prior year); cash and equivalents C$1,075.1M + short-term investments C$34.6M = C$1,109.7M; long-term debt C$996.5M (net cash ~C$113M); weighted average diluted shares 435,632,000
• Q1 2026 MD&A quarterly trend table (same 6-K) — Q2 2025 C$877M + Q3 2025 C$615M + Q4 2025 C$1,201M + Q1 2026 C$845M = TTM revenue C$3,538M, converted at 1.408 USDCAD (2026-07-23) = ~US$2.51B
• 6-K furnished to SEC 2026-02-12 (Q4/FY2025 results news release) — FY2025 revenue C$3.48B (2024: C$3.14B); adjusted net earnings C$627M; adjusted EBITDA ~C$1.9B
• 40-F for fiscal year ended 2025-12-31, filed with SEC March 2026 (officer certifications dated 2026-03-19, accession 0001193125-26-116229) — audited annual financial statements and AIF
• Share price US$90.37 = NYSE close 2026-07-22 (stockanalysis.com / market data); 52-week range $68.96–$135.24; USDCAD 1.408 on 2026-07-23 (tradingeconomics)

Scenario Valuation

Five-year scenario ranges under the published methodology — the tables below are computed from these exact parameters at publication and sealed with this text. What each scenario assumes:

• Loss (5%): A major nuclear safety event, an AI-datacenter capex bust that guts new-reactor demand, or outright collapse of the US government partnership sends spot uranium back below US$50/lb and vaporizes the Westinghouse premium; CCJ retraces to pre-2024 levels (~33% of today's price).
• Bear (25%): Realized prices stall near current contract levels, definitive AP1000 agreements slip indefinitely, and Westinghouse stays a services annuity; exit at 5.5x consolidated sales — a Kazatomprom-like mature-miner multiple (~4-5x) plus modest credit for the equity-accounted stakes.
• Base (50%): Contract-book repricing toward the US$90/lb long-term price plus sales volumes growing toward ~35M lb lifts consolidated revenue ~8%/yr; Westinghouse compounds 6-10%/yr with one or two AP1000 projects underway. Exit 8x consolidated sales = ~5x for the mining/fuel business (top of mature-miner range, justified by 55% look-through EBITDA margins) plus ~3 turns representing the equity-accounted 49% Westinghouse and 40% Inkai stakes whose revenue is absent from the denominator; this already equates to ~14-15x look-through EV/EBITDA, a full multiple for a mature resource company.
• Bull (20%): Definitive US government agreements signed, multiple AP1000s under construction, Western supply squeeze pushes realized prices above US$100/lb, McArthur/Key Lake expands toward the licensed 25M lb/yr; a Westinghouse IPO or marker crystallizes ~US$35-40B of value (Cameco share ~$18B). 11x consolidated sales (~20x look-through EV/EBITDA) is priced-for-perfection territory even for this outcome.

Published range (present value): $22.39 – $70.92 · probability-weighted expected value $41.87 against $90.37 at drafting (0.46×) · base-case IRR −6.0%/yr. Gates: base IRR ≥ 15% and EV ≥ 1.3× — both passed at publication. Ranges are graded at the 1-year checkpoint and the 5-year horizon. This is a range, not a target.

Sensitivity — present value across growth × exit multiple

The shaded cell is the one today's price of $90.37 most closely implies. Find your own cell — we show our work rather than assert a number.

Kill Conditions

1. 1. Contract book erosion: the five-year average annual committed uranium delivery volume disclosed in Cameco's quarterly MD&A falls below 25M lb/yr for two consecutive quarters (Q1 2026 reading: over 28M lb/yr).
2. 2. Price regime break: the UxC long-term uranium price indicator prints below US$70/lb at two consecutive quarter-ends (March 31, 2026 reading: US$90/lb, per Cameco's Q1 2026 MD&A).
3. 3. Westinghouse conditionality fails: no definitive agreements between Westinghouse and the US government executed by June 30, 2027, or Cameco's annual outlook for its share of Westinghouse adjusted EBITDA is set below the US$370M 2026 floor in any subsequent annual guidance.
4. 4. Tier-one operational failure: full-year uranium production (Cameco's share) misses the low end of annual guidance by more than 10% in any year (for 2026: actual below ~17.5M lb vs 19.5-21.5M lb guided).
5. 5. Balance-sheet regime change: net debt exceeds 2x TTM adjusted EBITDA in any quarterly report (currently net cash) — the signature of a leveraging acquisition that changes the risk profile.

Risk Register

• Valuation — SEVERE: at $90.37 CCJ trades at ~15.6x EV/consolidated TTM sales and ~73x TTM adjusted net earnings; the $80B program is substantially priced in before definitive agreements exist.
• AP1000 execution — HIGH: the last US AP1000 build (Vogtle 3&4) ran ~$35B and seven years late; Westinghouse's new-build economics under the government framework are unproven, and Cameco's own outlook is explicitly conditional on agreements not yet signed.
• Westinghouse net losses and leverage — MEDIUM: Cameco's share of Westinghouse net loss was C$46M in Q1 2026 (finance costs US$120-135M/yr Cameco share); EBITDA-to-cash conversion depends on distributions (US$49M received in Q1).
• Government partnership terms — MEDIUM: the US government participates in Westinghouse value creation above agreed thresholds, capping Cameco's share of upside in exactly the scenarios that justify today's multiple.
• Kazakhstan/Inkai — MEDIUM: the January 2025 production suspension showed fragility; sulfuric acid supply, transport routing, and Kazakh fiscal changes threaten the 4.2M lb purchase allocation and dividends (US$124M received April 2026).
• CRA transfer-pricing dispute — LOW/MEDIUM: reassessments for 2003-2006 continue despite Cameco's Supreme Court win; a tail risk of cash tax and penalties.
• Commodity reversal — MEDIUM: per Cameco's own sensitivity, a US$5/lb drop in spot cuts revenue ~C$36M; a return to the US$60s would stall the realized-price escalator that drives the base case.
• Currency — LOW: CAD-reported financials against mostly USD-denominated sales; USDCAD moved from the 1.33 outlook assumption to 1.41 spot, distorting USD comparisons.

Theme Position

Effectively 100% of Cameco's revenue is nuclear-fuel-cycle: 2026 guidance splits consolidated revenue of C$3,130–3,370M into uranium (C$2,540–2,730M, ~79%) and fuel services/conversion (C$590–630M, ~19%), and every equity-accounted asset — 49% of Westinghouse (reactor services and AP1000 new-build), 40% of JV Inkai (ISR uranium), 49% of Global Laser Enrichment — sits inside the theme too. No other SEC-filing ticker (40-F/6-K) spans mining, conversion, fuel fabrication, reactor services, and reactor technology in one instrument.

Alternatives considered. Kazatomprom (KAP LI): the world's largest, lowest-cost producer at roughly half Cameco's sales multiple — but London GDRs of a Kazakh SOE with material custody/transit exposure through Russian-adjacent routes, no reactor-technology leg, and governance we cannot underwrite for a 5-year hold. BWX Technologies (BWXT): high-quality naval-reactor and SMR services with real backlog — but no uranium price torque, and it has re-rated as hard as anything in the theme. Sprott Physical Uranium Trust (U.UN): the clean way to own the commodity thesis without paying 15x sales for an operator — the honest answer for pure spot exposure, but it carries no operating leverage, no contract book, and no Westinghouse, which is the specific integrated angle this thesis exists to examine. Pre-revenue reactor developers (Oklo, NuScale) fail our framework outright: no revenue to underwrite. Cameco is the right vehicle for the theme; the problem in July 2026 is strictly the price.

Benchmark

Beating means CCJ total return from publication ($90.37, 2026-07-22) exceeds QQQ total return over the same 5-year window; at our probability-weighted PV of ~$42 we expect it will not from this price, which is why this is a watchlist note with a low-$30s framework entry rather than a buy. Success means beating QQQ's total window return from publication; the scoreboard grades this thesis against that bar, live, whether we like the answer or not.